Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 220

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer

Open access
Yu, Evan Y., Wilding, George, Posadas, Edwin, Gross, Mitchell, Culine, Stephane, Massard, Christophe, Morris, Michael J., Hudes, Gary, Calabrò, Fabio, Cheng, Shinta, Trudel, Géralyn C., Paliwal, Prashni, Sternberg, Cora N. · 2009 · Clinical Cancer Research

Abstract

Purpose: Antiproliferative and antiosteoclastic activity from preclinical models show potential for dasatinib, an oral SRC and SRC family kinase inhibitor, as a targeted therapy for patients with prostate cancer. This phase II study investigated the activity of dasatinib in patients with metastatic castration-resistant prostate cancer (CRPC). Experimental Design: Chemotherapy-naive men with CRPC and increasing prostate-specific antigen were treated with dasatinib 100 or 70 mg twice daily. Endpoints included changes in prostate-specific antigen, bone scans, measurable disease (Response Evaluation Criteria in Solid Tumor), and markers of bone metabolism. Following Prostate Cancer Working Group 2 guidelines, lack of progression according to Response Evaluation Criteria in Solid Tumor and bone scan was determined and reported at 12 and 24 weeks. Results: Forty-seven patients were enrolled and received dasatinib (initial dose 100 mg twice daily, n = 25; 70 mg twice daily, n = 22), of whom 41 (87%) had bone disease. Lack of progression was achieved in 20 (43%) patients at week 12 and in 9 (19%) patients at week 24. Of 41 evaluable patients, 21 (51%) patients achieved ≥40% reduction in urinary N-telopeptide by week 12, with 33 (80%) achieving some level of reduction anytime on study. Of 15 patients with elevated urinary N-telopeptide at baseline, 8 (53%) normalized on study. Of 40 evaluable patients, 24 (60%) had reduction in bone alkaline phosphatase at week 12 and 25 (63%) achieved some reduction on study. Dasatinib was generally well tolerated and treatment-related adverse events were moderate. Conclusions: This study provides encouraging evidence of dasatinib activity in bone and reasonable tolerability in chemotherapy-naive patients with metastatic CRPC. (Clin Cancer Res 2009;15(23):7421–8)

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-09-1691

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 220

Metadata

Authors
Yu, E. Y., Wilding, G., Posadas, E., Gross, M., Culine, S., Massard, C., Morris, M. J., Hudes, G., Calabrò, F., Cheng, S., Trudel, G. C., Paliwal, P., & Sternberg, C. N.
Venue
Clinical Cancer Research
Published
2009-11-30
Volume
15
Issue
23
Pages
7421-7428
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2118263555
Cited by
220
References
4
FWCI
25.92
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-09-1691
The paper
Yu, E. Y., Wilding, G., Posadas, E., Gross, M., Culine, S., Massard, C., Morris, M. J., Hudes, G., Calabrò, F., Cheng, S., Trudel, G. C., Paliwal, P., & Sternberg, C. N. (2009). Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-09-1691

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.